



The largest Russian
manufacturer of the
socially significant
pharmaceuticals

Creating drugs to save lives

since 1997

pharmasyntez.com



Company today

pharmasyntez.com

Company today

>320

Products in various dosage forms and therapeutic areas

>80%

Produced drugs are included in the List of Essential Medicines



Pharmasyntez group

Top-3 leading pharmaceutical manufacturer on the Russian market*:



Manufacturer No. 1 in 2024 for public procurement of packaged goods

*Ratings are based on the analytical data provided by DSM Group



pharmasyntez.com

// 4

Financial outcome 2023

33,4 billion rubles

Revenue for 2023, 37,3 billion rubles incl.VAT

9,6 billion rubles

EBITDA for 2023



Production capacity

Sterile dosage forms:



1 bln pcs a year

Solutions for infusion, powder for solution for infusion, concentrates, emulsions, lyophilized powders, microspheres

pre-filled syringes

vials

cartridges

ampoules

Non-sterile dosage forms:



30 bln pcs a year

Tablets, capsules, granules, suppositories, ointments, gels

tubes

blister packaging

The company's
portfolio includes
the following
medicines:

>320
INNs

01

HIV/AIDS drugs

02

NSAIDs

03

Endocrine medicines
(antidiabetic, hormonal,
fertility drugs and others)

04

Cardiovascular
drugs

05

COVID-19
drugs

11

Monoclonal antibodies

06

Oncology drugs

07

Antipsychotics

08

Antibiotics, Antiviral
and Antituberculosis

09


Anaesthetic drugs
and X-ray agents

10

Drugs for Rare
Diseases




History of the company





Geography of Pharmasyntez Group 5 high-tech facilities

Representative offices in all regions of Russia and in CIS countries*



* In full compliance with GMP requirements

Pharmasintez-Nord: Saint Petersburg

- 01 Antineoplastic drugs
- 02 Biosimilar drugs
- 03 Biotechnology products
- 04 Insulins



Pharmasyntez Tyumen

- 01 Infusion solutions
- 02 Antidiabetic drugs
- 03 Hormonal drugs
- 04 X-ray agents and cardiovascular drugs





Pharmasintez: Irkutsk

01 Anti-TB drugs

02 ARV drugs

03 Anti-COVID drugs

04 Antimicrobial drugs

05 Anti-viral drugs

06 Antifungal drugs

07 Antipsychotic drugs





BratskChemSyntez

01 INNs of pharmaceutical substances

pharmasyntez.com

// 14



East-pharm: Ussuriysk

- 01 Antimicrobial infusion solutions
- 02 NSAID infusion solutions
- 03 General infusion solutions





The Company's innovations

pharmasyntez.com

SATEREX®

- 01** INN:
Gozogliptin
- 02** For the treatment
of type II diabetes
- 03** Full cycle production
of the drug including
API synthesis is carried
out by the Company



PERCHLOZONE®

- 01 Thioureidoiminomethylpyridinium Perchlorate
- 02 For the treatment of pulmonary tuberculosis, including multidrug-resistant tuberculosis
- 03 Pharmasintez is a developer and sole manufacturer of the drug



License Agreements

In 2017–2021, the Company signed 7 license agreements:

3

Oncology

1

Cardiology

1


Psychiatry

1

HIV/AIDS

1

Endocrinology



In-House Drug Candidates

SEROGUARD®

- 01 Adesmapimod
- 02 For the prevention and treatment of adhesion formation
- 03 After surgery Phase III of clinical studies is underway



R&D centers

Work in the following fields of development:

- 01 Finished dosage forms
- 02 Ingredients
- 03 Biosimilars

The R&D center:

- 01 Develops about 20 medicinal products annually on average
- 02 Carries out a full-cycle development and solves problems of any complexity

3 centers
in Russia

>20
medicinal products
annually

Pharmasyntez: Efficient Business

Cooperation opportunities

01

Acquisition of licenses
for new developments



02

Acquisition of production
technologies



03

Establishment of joint ventures
for the production of medicines



04

Joint
developments



05

Creation of innovative
medicines



06

Collaboration
with R&D centers




Export geography

>60 INNs

registered and supplied on global markets, we are constantly expanding the horizons of our cooperation.

>150 INNs

are in the process of registration in 10 new countries



The Pharmasyntez Group of Companies is a leader in production of socially significant medicinal products in Russia

Our advantages:

01

«In-bulk»
transfer

02

Flexible
pricing policy

03

Creating
joint ventures

04

Creating
manufacturing sites


05

Production under
your brand

06

Individual approach
in cooperation with
each partner

Foreign GMP inspections



Our achievements:

TOP 10

Russian corporations in terms of growth in the retail commercial market by value: growth by 52% vs. 2022

The portfolio of the Pharmasyntez Group includes:

In the Russian Federation and Eurasia along with

3
invention applications

20
patents

Abroad:

52
invention applications

193
patents





Pharmasyntez Group provides
a continuously high degree of communication
and service and is open for cooperation

For international
cooperation

export@pharmasyntez.com



For general
issues:

info@pharmasyntez.com



For
media:

pr@pharmasyntez.com

